CONCORD, N.H. (AP) — New Hampshire is getting $1.7 million from two prescription drug manufacturers that billed the state’s Medicaid program for substandard or improperly marketed medications.
GlaxoSmithKline will pay the state $1.24 million because four drugs it marketed here between 2001-2005, including Paxil CR, did not meet strength and purity standards set by the FDA.
Drug maker Novartis will pay the state $489,000 because it promoted its anti-epileptic drug, Trileptal, for unapproved uses such as treatment of bipolar disorder and neuropathic pain.
People were interested in these podcasts
Senior Assistant Attorney General Jeff Cahill said no New Hampshire patients suffered harm as a result of the drug frauds.
Please read our comment policy before commenting.